The Mount Sinai CCOP (MSCCOP) has achieved a national reputation for excellence in community cancer care through its 18+ year participation in programs of the National Cancer Institute. The program has been continuously funded by the NCI since its inception in 1987. The MSCCOP seeks to continue to meet the community's need for innovative and relevant studies of promising therapeutic modalities and cancer control research. The ongoing mission of the Mount Sinai Community Clinical Oncology Program is to assure that every person in the region served is provided an opportunity for participation in national cancer prevention and treatment clinical trials. Additionally, we strive to provide education about cancer and the NCI clinical trials program. This grant application encompasses and articulates an ever-expanding vision for the MSCCOP. Goals for this grant cycle include: Increase patient access and accrual to cancer treatment, prevention and control protocols Increase MSCCOP's robust record in accrual of minorities, women, and underserved populations Establish a stronger and more cohesive affiliate network Strengthen relationships with and contributions to affiliated research bases Update data management systems that enhance staff efficiency and operational effectiveness Maintain high-quality data management Key strategies to increase patient access and accrual to research protocols include expanding participation in symptom management protocols, aligning with research bases which offer protocols of interest to MSCCOP patient populations, strengthening partnerships with community organizations serving the Latino/Hispanic community, formalizing the MSCCOP governance structure to enhance relationships with affiliate institutions, and increasing participation on committees of aligned research bases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045564-25
Application #
8085891
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
1987-07-13
Project End
2013-05-31
Budget Start
2011-06-01
Budget End
2013-05-31
Support Year
25
Fiscal Year
2011
Total Cost
$572,575
Indirect Cost
Name
Mount Sinai Medical Center (Miami Beach)
Department
Type
DUNS #
046025144
City
Miami Beach
State
FL
Country
United States
Zip Code
33140
Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20

Showing the most recent 10 out of 45 publications